Dr. Harshman Discusses the Potential for New RCC Treatments

Lauren C. Harshman, MD
Published: Thursday, May 10, 2018



Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses the potential for new treatment options in renal cell carcinoma (RCC).

In nonmetastatic RCC, there has not been much progress in developing treatment beyond resection of the primary tumor, says Harshman. Still, a large number of patients, especially those with higher-stage disease, have a very high risk of recurrence. Harshman says that in 40 years of moving agents up from the metastatic setting, there has only been 1 positive trial, which ended up being countered by a negative trial. This trial was with sunitinib (Sutent), and it failed to improve progression-free survival when used prior to cytoreductive nephrectomy.

There are 3 targeted therapy studies that will mature in the coming year, says Harshman. Additionally, there has been excitement with checkpoint inhibitors. The ability to test checkpoint inhibitors earlier in the disease course with surgery make sense, Harshman explains.
SELECTED
LANGUAGE


Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses the potential for new treatment options in renal cell carcinoma (RCC).

In nonmetastatic RCC, there has not been much progress in developing treatment beyond resection of the primary tumor, says Harshman. Still, a large number of patients, especially those with higher-stage disease, have a very high risk of recurrence. Harshman says that in 40 years of moving agents up from the metastatic setting, there has only been 1 positive trial, which ended up being countered by a negative trial. This trial was with sunitinib (Sutent), and it failed to improve progression-free survival when used prior to cytoreductive nephrectomy.

There are 3 targeted therapy studies that will mature in the coming year, says Harshman. Additionally, there has been excitement with checkpoint inhibitors. The ability to test checkpoint inhibitors earlier in the disease course with surgery make sense, Harshman explains.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x